{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:19:31Z","timestamp":1793899171920,"version":"4.8.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40257-025-00952-w","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:59:50Z","timestamp":1758740390000},"page":"981-1002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Safety Data of Dupilumab for the Treatment of Moderate\u2011to\u2011Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults"],"prefix":"10.1007","volume":"26","author":[{"given":"Richard G.","family":"Langley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Gherardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7712-6862","authenticated-orcid":false,"given":"Marius","family":"Ardeleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"Rodr\u00edguez-Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7371-6486","authenticated-orcid":false,"given":"Ashish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5345-678X","authenticated-orcid":false,"given":"Ana B.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9285-8164","authenticated-orcid":false,"given":"Brad","family":"Shumel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal A.","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"issue":"4","key":"952_CR1","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1111\/ijd.14763","volume":"59","author":"G Birdi","year":"2020","unstructured":"Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020;59(4):e75-91.","journal-title":"Int J Dermatol"},{"issue":"2","key":"952_CR2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/jdv.19500","volume":"38","author":"K Eyerich","year":"2024","unstructured":"Eyerich K, Gooderham MJ, Silvestre JF, Shumack SP, Mendes-Bastos P, Aoki V, et al. Real-world clinical, psychosocial, and economic burden of atopic dermatitis: results from a multicountry study. J Eur Acad Dermatol Venereol. 2024;38(2):340\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"952_CR3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZCC Fuxench","year":"2019","unstructured":"Fuxench ZCC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Investig Dermatol. 2019;139(3):583\u201390.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"952_CR4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","volume":"137","author":"AM Drucker","year":"2017","unstructured":"Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Investig Dermatol. 2017;137(1):26\u201330.","journal-title":"J Investig Dermatol"},{"issue":"4","key":"952_CR5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2500\/aap.2017.38.4054","volume":"38","author":"JI Silverberg","year":"2017","unstructured":"Silverberg JI. Atopic dermatitis treatment: current state of the art and emerging therapies. Allergy Asthma Proc. 2017;38(4):243\u20139.","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"952_CR6","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","volume":"5","author":"M Boguniewicz","year":"2017","unstructured":"Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519\u201331.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"952_CR7","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s13555-021-00558-0","volume":"11","author":"C Griffiths","year":"2021","unstructured":"Griffiths C, de Bruin-Weller M, Deleuran M, Fargnoli MC, Staumont-Sall\u00e9 D, Hong CH, et al. Dupilumab in adults with moderate-to-severe atopic dermatitis and prior use of systemic non-steroidal immunosuppressants: analysis of four phase 3 trials. Dermatol Ther (Heidelb). 2021;11(4):1357\u201372.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6","key":"952_CR8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.anai.2023.03.010","volume":"130","author":"M Boguniewicz","year":"2023","unstructured":"Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg JI. Atopic dermatitis yardstick update. Ann Allergy Asthma Immunol. 2023;130(6):811\u201320.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"952_CR9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"DK Chu","year":"2024","unstructured":"AAAI\/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274\u2013312.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"(5-6)","key":"952_CR10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1159\/000540920","volume":"240","author":"LF Eichenfield","year":"2024","unstructured":"Eichenfield LF, Boguniewicz M, Lauren CT, Leung DYM, Levy ML, Schneider LC, et al. Systemic therapy for atopic dermatitis in children and adolescents: a US expert consensus. Dermatology. 2024;240(5-6):897\u2013909.\u00a0https:\/\/doi.org\/10.1159\/000540920.","journal-title":"Dermatology"},{"issue":"9","key":"952_CR11","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I\u2014systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"952_CR12","unstructured":"Dupilumab. Prescribing information. Tarrytown (NY): Regeneron Pharmaceuticals Inc.; 2024. Revised: September 2024."},{"issue":"5","key":"952_CR13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"952_CR14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc'h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204.","journal-title":"Allergy"},{"key":"952_CR15","unstructured":"European Medicines Agency. Dupilumab EPAR. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dupixent. Accessed 12 Nov 2024."},{"issue":"4","key":"952_CR16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","volume":"21","author":"LA Beck","year":"2020","unstructured":"Beck LA, Tha\u00e7i D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21(4):567\u201377.","journal-title":"Am J Clin Dermatol"},{"issue":"10086","key":"952_CR17","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet"},{"issue":"5","key":"952_CR18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178(5):1083\u2013101.","journal-title":"Br J Dermatol"},{"issue":"10356","key":"952_CR19","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab phase 3 in children < 6 years with uncontrolled atopic dermatitis. Lancet. 2022;400(10356):908\u201319.","journal-title":"Lancet"},{"issue":"24","key":"952_CR20","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"2","key":"952_CR21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","volume":"156","author":"M Worm","year":"2020","unstructured":"Worm M, Simpson EL, Tha\u00e7i D, Bissonnette R, Lacour JP, Beissert S, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131\u201343.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"952_CR22","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bjd.19460","volume":"184","author":"MJ Cork","year":"2021","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, et al. Dupilumab provides favourable long-term safety and efficacy in children aged \u2265 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2021;184(5):857\u201370.","journal-title":"Br J Dermatol"},{"issue":"3","key":"952_CR23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","volume":"23","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365\u201383.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"952_CR24","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1007\/s13555-023-01016-9","volume":"13","author":"MJ Cork","year":"2023","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, Arkwright PD, Chen Z, Thomas RB, et al. Dupilumab safety and efficacy in a phase III open-label extension trial in children 6\u201311 years of age with severe atopic dermatitis. Dermatol Ther (Heidelb). 2023;13(11):2697\u2013719.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"8","key":"952_CR25","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","volume":"160","author":"LA Beck","year":"2024","unstructured":"Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A, et al. Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol. 2024;160(8):805\u201312.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"952_CR26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis. JAMA Dermatol. 2020;156(1):44\u201356.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"952_CR27","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282\u201393.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"952_CR28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","volume":"23","author":"LA Beck","year":"2022","unstructured":"Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):393\u2013408.","journal-title":"Am J Clin Dermatol"},{"key":"952_CR29","unstructured":"ICH Harmonised Tripartite Guideline: Clinical safety data management: definitions and standards for expedited reporting E2A. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1994. https:\/\/database.ich.org\/sites\/default\/files\/E2A_Guideline.pdf. Accessed 12 Nov 2024."},{"issue":"5","key":"952_CR30","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/bjd.18434","volume":"182","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182(5):1120\u201335.","journal-title":"Br J Dermatol"},{"issue":"10","key":"952_CR31","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2022;10(10):2695\u2013709.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"952_CR32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40272-021-00459-x","volume":"23","author":"AS Paller","year":"2021","unstructured":"Paller AS, Wollenberg A, Siegfried E, Tha\u00e7i D, Cork MJ, Arkwright PD, et al. Laboratory safety of dupilumab in patients aged 6\u201311 years with severe atopic dermatitis: results from a phase III clinical trial. Pediatr Drugs. 2021;23(5):515\u201327.","journal-title":"Pediatr Drugs"},{"issue":"2","key":"952_CR33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.16928","volume":"35","author":"AS Paller","year":"2021","unstructured":"Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP, et al. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to < 6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2021;35(2):464\u201375.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"952_CR34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","volume":"82","author":"M Deleuran","year":"2020","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377\u201388.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"952_CR35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","volume":"315","author":"C Bachert","year":"2016","unstructured":"Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469\u201379.","journal-title":"JAMA"},{"issue":"2","key":"952_CR36","doi-asserted-by":"crossref","first-page":"AB31","DOI":"10.1016\/j.jaci.2020.12.149","volume":"147","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Simpson E, Weidinger S, Barbarot S, Brignoli L, Mnif T, et al. Children with atopic dermatitis (AD) have a high burden of atopic comorbidities: results from a large worldwide survey. J Allergy Clin Immunol. 2021;147(2):AB31.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"952_CR37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","volume":"74","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NMH, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"952_CR38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/DER.0000000000000161","volume":"27","author":"SH Yu","year":"2016","unstructured":"Yu SH, Attarian H, Zee P, Silverberg JI. Burden of sleep and fatigue in US adults with atopic dermatitis. Dermatitis. 2016;27(2):50\u20138.","journal-title":"Dermatitis"},{"issue":"6","key":"952_CR39","first-page":"411","volume":"8","author":"K Scherer","year":"2010","unstructured":"Scherer K, Spoerl D, Bircher AJ. Adverse drug reactions to biologics. J Dtsch Dermatol Ges. 2010;8(6):411\u201326.","journal-title":"J Dtsch Dermatol Ges"},{"key":"952_CR40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","volume":"7","author":"A St. Clair-Jones","year":"2020","unstructured":"St. Clair-Jones A, Prignano F, Goncalves J. Understanding and minimizing injection-site pain following subcutaneous administration of biologics: a narrative review. Rheumatol Ther. 2020;7:741\u201357.","journal-title":"Rheumatol Ther."},{"issue":"3","key":"952_CR41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","volume":"181","author":"B Akinlade","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459\u201373.","journal-title":"Br J Dermatol"},{"issue":"1","key":"952_CR42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40257-020-00577-1","volume":"22","author":"A Bansal","year":"2021","unstructured":"Bansal A, Simpson EL, Paller AS, Siegfried EC, Blauvelt A, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials for adolescents with atopic dermatitis or asthma. Am J Clin Dermatol. 2021;22(1):101\u201315.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"952_CR43","first-page":"796","volume":"43","author":"N Ohmachi","year":"1994","unstructured":"Ohmachi N, Sasabe T, Kojima M, Adachi J, Endo K, Fukuzumi T, et al. Eye complications in atopic dermatitis. Arerugi. 1994;43(7):796\u20139.","journal-title":"Arerugi"},{"issue":"1","key":"952_CR44","first-page":"21","volume":"19","author":"JA Garrity","year":"1984","unstructured":"Garrity JA, Liesegang TJ. Ocular complications of atopic dermatitis. Can J Ophthalmol. 1984;19(1):21\u20134.","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"952_CR45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bjo.82.1.82","volume":"82","author":"E Uchio","year":"1998","unstructured":"Uchio E, Miyakawa K, Ikezawa Z, Ohno S. Systemic and local immunological features of atopic dermatitis patients with ocular complications. Br J Ophthalmol. 1998;82(1):82\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"952_CR46","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, Kwatra SG, Kim BS, Laws E, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023;29(5):1180\u201390.","journal-title":"Nat Med"},{"issue":"10209","key":"952_CR47","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomized, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638\u201350.","journal-title":"Lancet"},{"issue":"Supplement_2","key":"952_CR48","doi-asserted-by":"crossref","first-page":"ljae266.061","DOI":"10.1093\/bjd\/ljae266.061","volume":"191","author":"P Asbell","year":"2024","unstructured":"Asbell P, Akpek EK, Chamberlain W, Chen Z, Coleman A, Rossi AB, et al. Treatment of conjunctivitis in dupilumab-treated patients with atopic dermatitis: an observational study. Br J Dermatol. 2024;191(Supplement_2):ljae266.061.","journal-title":"Br J Dermatol"},{"issue":"3","key":"952_CR49","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100042","volume":"1","author":"M Kamata","year":"2021","unstructured":"Kamata M, Tada Y. A literature review of real-world effectiveness and safety of dupilumab for atopic dermatitis. JID Innov. 2021;1(3):100042.","journal-title":"JID Innov."},{"key":"952_CR50","unstructured":"European Medicines Agency. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders_en.pdf-0. Accessed 13 Nov 2024."},{"issue":"1","key":"952_CR51","volume":"9","author":"GR Burmester","year":"2023","unstructured":"Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1):e002735.","journal-title":"RMD Open"},{"key":"952_CR52","unstructured":"US Food and Drug Administration. RINVOQ NDA approval letter. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2022\/211675Orig1s004ltr.pdf. Accessed 13 Nov 2024."},{"key":"952_CR53","unstructured":"US Food and Drug Administration. OLUMIANT approval letter. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2022\/207924Orig1s007ltr.pdf. Accessed 13 Nov 2024."},{"key":"952_CR54","unstructured":"US Food and Drug Administration. CIBINQO NDA approval letter. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213871s000lbl.pdf. Accessed 13 Nov 2024."},{"key":"952_CR55","unstructured":"Center for Drug Evaluation and Research. CDER Risk Assessment Review: Cibinqo. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/213871Orig1s000RiskR.pdf. Accessed 13 Nov 2024."},{"key":"952_CR56","unstructured":"Center for Drug Evaluation and Research. CDER Risk Assessment Review: Olumiant. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/207924Orig1s000RiskR.pdf. Accessed 13 Nov 2024."},{"key":"952_CR57","unstructured":"Center for Drug Evaluation and Research. CDER risk assessment review: Rinvoq. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211675Orig1s000RiskR.pdf. Accessed 13 Nov 2024."},{"issue":"2","key":"952_CR58","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.sder.2008.04.002","volume":"27","author":"TR Hata","year":"2008","unstructured":"Hata TR, Gallo RL. Antimicrobial peptides, skin infections, and atopic dermatitis. Semin Cutan Med Surg. 2008;27(2):144\u201350.","journal-title":"Semin Cutan Med Surg"},{"issue":"5","key":"952_CR59","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2340\/00015555-1996","volume":"95","author":"LA Salah","year":"2015","unstructured":"Salah LA, Faergemann J. A retrospective analysis of skin bacterial colonisation, susceptibility and resistance in atopic dermatitis and impetigo patients. Acta Derm Venereol. 2015;95(5):532\u20135.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"952_CR60","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12016-016-8548-5","volume":"51","author":"PY Ong","year":"2016","unstructured":"Ong PY, Leung DYM. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;51(3):329\u201337.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"952_CR61","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jid.2017.01.030","volume":"137","author":"SM Langan","year":"2017","unstructured":"Langan SM, Abuabara K, Henrickson SE, Hoffstad O, Margolis DJ. Increased risk of cutaneous and systemic infections in atopic dermatitis\u2014a cohort study. J Investig Dermatol. 2017;137(6):1375\u20137.","journal-title":"J Investig Dermatol"},{"issue":"10","key":"952_CR62","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86955","volume":"1","author":"IA Myles","year":"2016","unstructured":"Myles IA, Williams KW, Reckhow JD, Jammeh ML, Pincus NB, Sastalla I, et al. Transplantation of human skin microbiota in models of atopic dermatitis. JCI Insight. 2016;1(10):e86955.","journal-title":"JCI Insight"},{"issue":"3","key":"952_CR63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4168\/aair.2018.10.3.207","volume":"10","author":"BE Kim","year":"2018","unstructured":"Kim BE, Leung DYM. Significance of skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol Res. 2018;10(3):207\u201315.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"5","key":"952_CR64","volume":"2","author":"LA Beck","year":"2022","unstructured":"Beck LA, Cork MJ, Amagai M, De Benedetto A, Kabashima K, Hamilton JD, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innov. 2022;2(5):100131.","journal-title":"JID Innov"},{"issue":"2","key":"952_CR65","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jaci.2009.05.020","volume":"124","author":"LA Beck","year":"2009","unstructured":"Beck LA, Boguniewicz M, Hata T, Schneider LC, Hanifin J, Gallo R, et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol. 2009;124(2):260\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"952_CR66","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2011.06.003","volume":"128","author":"MD Howell","year":"2011","unstructured":"Howell MD, Gao P, Kim BE, Lesley LJ, Streib JE, Taylor PA, et al. The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections. J Allergy Clin Immunol. 2011;128(5):1006\u201314.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"952_CR67","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/cid\/cir952","volume":"54","author":"JL Reed","year":"2012","unstructured":"Reed JL, Scott DE, Bray M. Eczema vaccinatum. Clin Infect Dis. 2012;54(6):832\u201340.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"952_CR68","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.anai.2017.10.019","volume":"120","author":"S Narla","year":"2018","unstructured":"Narla S, Silverberg JI. Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults. Ann Allergy Asthma Immunol. 2018;120(1):66-72.e11.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"952_CR69","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2018.11.028","volume":"80","author":"L Serrano","year":"2019","unstructured":"Serrano L, Patel KR, Silverberg JI. Association between atopic dermatitis and extracutaneous bacterial and mycobacterial infections: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(4):904\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"952_CR70","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bjd.19825","volume":"185","author":"C Droitcourt","year":"2021","unstructured":"Droitcourt C, Vittrup I, Dupuy A, Egeberg A, Thyssen JP. Risk of systemic infections requiring hospitalization in children with atopic dermatitis: a Danish retrospective nationwide cohort study. Br J Dermatol. 2021;185(1):119\u201329.","journal-title":"Br J Dermatol"},{"issue":"5","key":"952_CR71","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jaip.2021.11.034","volume":"10","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, Rubini NPM, Pires MC, Rossi AB, Zhang A, Chen Z, et al. Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract. 2022;10(5):1279 (85.e1).","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"952_CR72","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1111\/all.15432","volume":"77","author":"E Berdyshev","year":"2022","unstructured":"Berdyshev E, Goleva E, Bissonnette R, Bronova I, Bronoff AS, Richers BN, et al. Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. Allergy. 2022;77(11):3388\u201397.","journal-title":"Allergy"},{"issue":"8","key":"952_CR73","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jaip.2023.04.052","volume":"11","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, De Benedetto A, Boguniewicz M, Ong PY, Lussier S, Villarreal M, et al. Phenotypic and endotypic determinants of atopic dermatitis severity from the ADRN registry. J Allergy Clin Immunol Pract. 2023;11(8):2504\u201315.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"952_CR74","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jid.2019.05.024","volume":"140","author":"C Callewaert","year":"2020","unstructured":"Callewaert C, Nakatsuji T, Knight R, Kosciolek T, Vrbanac A, Kotol P, et al. IL-4R\u03b1 blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis. J Invest Dermatol. 2020;140(1):191-202.e7.","journal-title":"J Invest Dermatol"},{"key":"952_CR75","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.jid.2021.02.696","volume":"141","author":"LA Beck","year":"2021","unstructured":"Beck LA, Boguniewicz M, Hata T, Chiesa Fuxench ZC, Simpson E, De Benedetto A, et al. Effect of dupilumab on the host-microbe interface in atopic dermatitis. J Investig Dermatol. 2021;141:S116 (Abstract #666).","journal-title":"J Investig Dermatol"},{"key":"952_CR76","unstructured":"Goleva E, Berdyshev E, Kreimer S, et al. Dupilumab inhibits expression of fibronectin and fibrinogen, skin proteins that regulate Staphylococcus aureus adhesion to atopic dermatitis skin. 12th Georg Rajka International Symposium on Atopic Dermatitis, Oct 17\u201319, 2022; hybrid congress: virtual and Montreal, Quebec, Canada."},{"issue":"5","key":"952_CR77","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jaip.2023.03.020","volume":"11","author":"DYM Leung","year":"2023","unstructured":"Leung DYM, Bissonnette R, Kreimer S, Berdyshev E, Bafna S, Lyubchenko T, et al. Dupilumab inhibits vascular leakage of blood proteins into atopic dermatitis skin. J Allergy Clin Immunol Pract. 2023;11(5):1421\u20138.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"952_CR78","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri3831","volume":"15","author":"TA Wynn","year":"2015","unstructured":"Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15(5):271\u201382.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"952_CR79","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350.","journal-title":"Nat Rev Drug Discov"},{"key":"952_CR80","unstructured":"Centers for Disease Control and Prevention (CDC). Parasites\u2014Enterobiasis (also known as pinworm infection): epidemiology & risk factors. https:\/\/www.cdc.gov\/pinworm\/about\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/parasites\/pinworm. Accessed 13 Nov 2024."},{"issue":"1","key":"952_CR81","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jaad.2018.07.048","volume":"80","author":"A Blauvelt","year":"2019","unstructured":"Blauvelt A, Simpson EL, Tyring SK, Purcell LA, Shumel B, Petro CD, et al. Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2019;80(1):158-67.e1.","journal-title":"J Am Acad Dermatol"},{"key":"952_CR82","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.jaad.2024.08.082","volume":"92","author":"TV Nguyen","year":"2025","unstructured":"Nguyen TV, Marcus AF, Sinnott SJ, Coleman A, Peralta C, Levy S, et al. Commentary: Response to \u201cDupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.\u201d J Am Acad Dermatol. 2025;92:e41\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"952_CR83","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/bjd\/ljad072","volume":"189","author":"J Wan","year":"2023","unstructured":"Wan J, Shin DB, Syed MN, Abuabara K, Lemeshow AR, Chiesa Fuxench ZC, et al. Malignancy risk in patients with atopic dermatitis: a population-based cohort study. Br J Dermatol. 2023;189:53\u201361.","journal-title":"Br J Dermatol"},{"key":"952_CR84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000209289","volume":"219","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez-Vidaurre C, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology. 2009;219:7\u201321.","journal-title":"Dermatology"},{"key":"952_CR85","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaad.2015.02.1116","volume":"72","author":"L Legendre","year":"2015","unstructured":"Legendre L, Barnetche T, Mazereeuw-Hautier J, Nicolas M, Dedee M, Carle P. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;72:992\u20131002.","journal-title":"J Am Acad Dermatol"},{"key":"952_CR86","doi-asserted-by":"publisher","unstructured":"Ong PY. Is dupilumab use in atopic dermatitis associated with cutaneous T-cell lymphoma? J Allergy Clin Immunol. 2025;155(5):1481\u20132. https:\/\/doi.org\/10.1016\/j.jaci.2025.02.002.","DOI":"10.1016\/j.jaci.2025.02.002"},{"key":"952_CR87","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1111\/jdv.20141","volume":"39","author":"R Stuver","year":"2025","unstructured":"Stuver R, Dusza S, Epstein-Peterson ZD, Ghione P, Horwitz SM, Johnson W, et al. Cutaneous T-cell lymphoma and dupilumab use: a retrospective matched cohort study of clinical characteristics and treatment outcomes. J Eur Acad Dermatol Venereol. 2025;39:e114\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"952_CR88","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/art.42558","volume":"75","author":"CD Hughes","year":"2023","unstructured":"Hughes CD, Nathan J, Mathew L, Pink AE, Woolf RT, Smith C, et al. Characterization of a musculoskeletal syndrome of enthesitis and arthritis in patients with atopic dermatitis treated with dupilumab, an IL-4\/13 inhibitor. Arthritis Rheumatol. 2023;75(10):1793\u20137.","journal-title":"Arthritis Rheumatol"},{"key":"952_CR89","unstructured":"Dalia Y, Johnson SM. Case report: first reported case of facial rash after dupilumab therapy. 2018. https:\/\/practicaldermatology.com\/youngmd-connect\/resident-resource-center\/case-report-first-reported-case-of-facial-rash-after-dupilumab-therapy-call-for-abstracts\/20499\/. Accessed 13 Nov 2024."},{"issue":"9","key":"952_CR90","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jdcr.2018.08.027","volume":"4","author":"R Suresh","year":"2018","unstructured":"Suresh R, Murase JE. The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy. JAAD Case Rep. 2018;4(9):899\u2013904.","journal-title":"JAAD Case Rep."},{"issue":"1","key":"952_CR91","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jaad.2019.06.026","volume":"82","author":"RA Waldman","year":"2020","unstructured":"Waldman RA, DeWane ME, Sloan B, Grant-Kels JM. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020;82(1):230\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"952_CR92","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/cod.13898","volume":"85","author":"M Napolitano","year":"2021","unstructured":"Napolitano M, Fabbrocini G, Patruno C. Allergic contact dermatitis to compositae: a possible cause of dupilumab-associated facial and neck dermatitis in atopic dermatitis patients? Contact Dermatitis. 2021;85(4):473\u20134.","journal-title":"Contact Dermatitis"},{"issue":"5","key":"952_CR93","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","volume":"84","author":"CE Jo","year":"2021","unstructured":"Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339\u201347.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"952_CR94","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2217\/imt-2021-0122","volume":"14","author":"A Dyba\u0142a","year":"2022","unstructured":"Dyba\u0142a A, Sernicola A, Gomes V, Carnicelli G, Muharremi R, Grieco T. Dupilumab facial redness: histologic characterization on a series of four cases. Immunotherapy. 2022;14(4):183\u20138.","journal-title":"Immunotherapy"},{"issue":"1","key":"952_CR95","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/pde.14434","volume":"38","author":"AL Fritz","year":"2021","unstructured":"Fritz AL, Lacy FA, Morrell DS. Angioedema: a potential complication of dupilumab in atopic dermatitis. Pediatr Dermatol. 2021;38(1):237\u20138.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"952_CR96","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/09546634.2019.1624683","volume":"32","author":"HD Heibel","year":"2021","unstructured":"Heibel HD, Hendricks AJ, Foshee JP, Shi VY. Rosacea associated with dupilumab therapy. J Dermatolog Treat. 2021;32(1):114\u20136.","journal-title":"J Dermatolog Treat"},{"key":"952_CR97","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13223-020-00458-6","volume":"16","author":"DH Jang","year":"2020","unstructured":"Jang DH, Lee JI, Bae JY, Jung HJ, Park MY, Ahn J. Facial erythema after the treatment of dupilumab in SLE patient. Allergy Asthma Clin Immunol. 2020;16:60.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"952_CR98","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.3390\/jcm9061982","volume":"9","author":"DH Jang","year":"2020","unstructured":"Jang DH, Heo SJ, Jung HJ, Park MY, Seo SJ, Ahn J. Retrospective study of dupilumab treatment for moderate to severe atopic dermatitis in Korea: efficacy and safety of dupilumab in real-world practice. J Clin Med. 2020;9(6):1982.","journal-title":"J Clin Med"},{"issue":"1","key":"952_CR99","doi-asserted-by":"crossref","first-page":"23539","DOI":"10.1038\/s41598-021-02950-4","volume":"11","author":"DH Jang","year":"2021","unstructured":"Jang DH, Heo SJ, Kook HD, Lee DH, Jung HJ, Park MY, et al. A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world. Sci Rep. 2021;11(1):23539.","journal-title":"Sci Rep"},{"issue":"5","key":"952_CR100","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/pde.14799","volume":"38","author":"PL McKenzie","year":"2021","unstructured":"McKenzie PL, Rangu S, Treat JR, Castelo-Soccio L. Experience using dupilumab for pediatric atopic dermatitis at a tertiary care center: inadequate response and adverse events. Pediatr Dermatol. 2021;38(5):1178\u201384.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"952_CR101","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14888","volume":"34","author":"T Miyagaki","year":"2021","unstructured":"Miyagaki T, Okano T, Nakajima K, Mitsuishi S, Kishi A, Miyano K, et al. A case of facial redness in atopic dermatitis occurring during dupilumab treatment successfully treated with topical delgocitinib ointment. Dermatol Ther. 2021;34(2):e14888.","journal-title":"Dermatol Ther"},{"issue":"1","key":"952_CR102","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.alit.2020.07.001","volume":"70","author":"M Nakanishi","year":"2021","unstructured":"Nakanishi M, Tamagawa-Mineoka R, Arakawa Y, Masuda K, Katoh N. Dupilumab-resistant facial erythema\u2014dermoscopic, histological and clinical findings of three patients. Allergol Int. 2021;70(1):156\u20138.","journal-title":"Allergol Int"},{"issue":"6","key":"952_CR103","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4168\/aair.2020.12.6.1063","volume":"12","author":"SH Seok","year":"2020","unstructured":"Seok SH, An JH, Shin JU, Lee HJ, Kim DH, Yoon MS, et al. Facial redness in atopic dermatitis patients treated with dupilumab: a case series. Allergy Asthma Immunol Res. 2020;12(6):1063\u20135.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"11","key":"952_CR104","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/jdv.18327","volume":"36","author":"J Ahn","year":"2022","unstructured":"Ahn J, Lee DH, Na CH, Shim DH, Choi YS, Jung HJ, et al. Facial erythema in patients with atopic dermatitis treated with dupilumab\u2014a descriptive study of morphology and aetiology. J Eur Acad Dermatol Venereol. 2022;36(11):2140\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"952_CR105","volume":"11","author":"A Raimondo","year":"2021","unstructured":"Raimondo A, Lembo S. Atopic dermatitis: epidemiology and clinical phenotypes. Dermatol Pract Concept. 2021;11(4): e2021146.","journal-title":"Dermatol Pract Concept."},{"key":"952_CR106","first-page":"204062232110029","volume":"12","author":"G Girolomoni","year":"2021","unstructured":"Girolomoni G, de Bruin-Weller M, Aoki V, Kabashima K, Deleuran M, Puig L, et al. Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chron Dis. 2021;12:20406223211002980.","journal-title":"Ther Adv Chron Dis."},{"issue":"5","key":"952_CR107","first-page":"1643","volume":"11","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Paller AS, Siegfried EC, Tha\u00e7i D, Wollenberg A, Cork MJ, et al. Dupilumab demonstrates rapid and consistent improvement in extent and signs of atopic dermatitis across all anatomical regions in pediatric patients 6 years of age and older. Dermatol Ther (Heidelb). 2021;11(5):1643\u201356.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"1","key":"952_CR108","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","volume":"120","author":"M Boguniewicz","year":"2018","unstructured":"Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"952_CR109","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients\u2019 Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657\u201382. Erratum in: J Eur Acad Dermatol Venereol. 2019;33(7):1436.","DOI":"10.1111\/jdv.14891"},{"key":"952_CR110","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients\u2019 Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part\u00a0II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378.","DOI":"10.1111\/jdv.14888"},{"issue":"2","key":"952_CR111","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40257-020-00583-3","volume":"22","author":"EC Siegfried","year":"2021","unstructured":"Siegfried EC, Bieber T, Simpson EL, Paller AS, Beck LA, Boguniewicz M, et al. Effect of dupilumab on laboratory parameters in adolescents with atopic dermatitis: results from a randomized, placebo-controlled, phase 3 clinical trial. Am J Clin Dermatol. 2021;22(2):243\u201355.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"952_CR112","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jaci.2019.08.039","volume":"144","author":"J Allinne","year":"2019","unstructured":"Allinne J, Scott G, Lim WK, Birchard D, Erjef\u00e4lt JS, Sand\u00e9n C, et al. IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation. J Allergy Clin Immunol. 2019;144(6):1624-37.e1610.","journal-title":"J Allergy Clin Immunol"},{"key":"952_CR113","first-page":"A5555","volume":"199","author":"J Allinne","year":"2019","unstructured":"Allinne J, Scott G, Birchard D, Asrat S, Nagashima K, Le Floc\u2019h A, et al. Broader impact of IL-4R\u03b1 blockade than IL-5 blockade on mediators of type 2 inflammation and lung pathology in a house dust mite-induced asthma mouse model. Am J Respir Crit Care Med. 2019;199:A5555.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"952_CR114","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40272-022-00553-8","volume":"25","author":"AS Paller","year":"2023","unstructured":"Paller AS, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Gonzalez ME, et al. Laboratory safety from a 16-week phase 3 study of dupilumab in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. Paediatr Drugs. 2023;25(1):67\u201377.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"952_CR115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.iac.2016.08.008","volume":"37","author":"JL Thijs","year":"2017","unstructured":"Thijs JL, de Bruin-Weller MS, Hijnen D. Current and future biomarkers in atopic dermatitis. Immunol Allergy Clin N Am. 2017;37(1):51\u201361.","journal-title":"Immunol Allergy Clin N Am"},{"issue":"10","key":"952_CR116","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jid.2018.03.1517","volume":"138","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Villarreal M, Jepson B, Rafaels N, David G, Hanifin J, et al. Patients with atopic dermatitis colonized with Staphylococcus aureus have a distinct phenotype and endotype. J Investig Dermatol. 2018;138(10):2224\u201333.","journal-title":"J Investig Dermatol"},{"issue":"8","key":"952_CR117","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1346-8138.1990.tb01679.x","volume":"17","author":"H Mukai","year":"1990","unstructured":"Mukai H, Noguchi T, Kamimura K, Nishioka K, Nishiyama S. Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis. J Dermatol. 1990;17(8):477\u201381.","journal-title":"J Dermatol"},{"issue":"4","key":"952_CR118","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00403-011-1198-9","volume":"304","author":"K Kou","year":"2012","unstructured":"Kou K, Aihara M, Matsunaga T, Chen H, Taguri M, Morita S, et al. Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis. Arch Dermatol Res. 2012;304(4):305\u201312.","journal-title":"Arch Dermatol Res"},{"issue":"Suppl4","key":"952_CR119","first-page":"P93","volume":"188","author":"AD Irvine","year":"2023","unstructured":"Irvine AD, Paller AS, Horowitz JE, Farrell A, Hatsell S, Ehmann P, et al. Dupilumab treatment in children with moderate-to-severe atopic dermatitis increases levels of bone mineralization biomarkers. Br J Dermatol. 2023;188(Suppl4):P93.","journal-title":"Br J Dermatol"},{"issue":"3","key":"952_CR120","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/jdv.16895","volume":"35","author":"IM Mukovozov","year":"2021","unstructured":"Mukovozov IM, Morra DE, Giustini D, Tadrous M, Cheung AM, Drucker AM. Atopic dermatitis and bone health: a systemic review. J Eur Acad Dermatol Venereol. 2021;35(3):615\u201328.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"952_CR121","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/pai.12315","volume":"26","author":"JI Silverberg","year":"2015","unstructured":"Silverberg JI. Association between childhood atopic dermatitis, malnutrition, and low bone mineral density: a US population-based study. Pediatr Allergy Immunol. 2015;26(1):54\u201361.","journal-title":"Pediatr Allergy Immunol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00952-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00952-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00952-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:45:52Z","timestamp":1763048752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00952-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":121,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00952-w","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"9 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Regeneron Pharmaceuticals Inc. and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"R.G. Langley received honoraria as a principal investigator, scientific advisor, or speaker for AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers-Squibb, Dermavant, Dermira, Eli Lilly, GlaxoSmithKline, Janssen, Leo Pharma, Novartis, Ortho Dermatologics, Pfizer, Sanofi-Genzyme, Sun Pharma, UCB Pharma, and Union. G. Gherardi, A. Rodr\u00edguez-Marco, and A.B. Rossi are employees of Sanofi and may hold stock and\/or stock options in the company. A. Coleman, M. Ardeleanu, S. Levy, A. Bansal, Z. Chen, B. Shumel, and F.A. Khokhar are employees and shareholders of Regeneron Pharmaceuticals Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing (1) once the product and indication has been approved by major health authorities (e.g., FDA, EMA, PMDA, etc.) or development of the product has been discontinued globally for all indications on or after April 2020 and there are no plans for future development (2) if there is legal authority to share the data and (3) there is not a reasonable likelihood of participant re-identification. Submit requests to\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Ethical approval was obtained for individual studies included in this analysis. All trials were conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guideline, and applicable regulatory requirements. Independent data and safety monitoring committees conducted blinded monitoring of patient safety data. The local institutional review boards or ethics committees at each study center oversaw trial conduct and documentation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"For each trial, all patients or their parents\/guardians provided written informed consent before participating in the trial. Written informed consent was obtained from all patients and the patients\u2019 parents\/guardians prior to commencement of any study treatment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"A.C., A.B.R., B.S., and F.A.K. contributed to concept and design of the analyses described in this manuscript. Z.C. conducted the statistical analyses of the data. All authors interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and were accountable for the accuracy and integrity of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing (1) once the product and indication has been approved by major health authorities (e.g., FDA, EMA, PMDA, etc.) or development of the product has been discontinued globally for all indications on or after April 2020 and there are no plans for future development (2) if there is legal authority to share the data and (3) there is not a reasonable likelihood of participant re-identification. Submit requests to\n                      \n                      .","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}